Phase I combining a P-glycoprotein inhibitor, MS209, in combination with docetaxel in patients with advanced malignancies

Clinical Cancer Research

Volumn 11, Issue 17, 2005, Pages 6256-6260

  Diéras, Véronique ^a   Bonneterre, Jacques ^b   Laurence, Valérie ^a   Degardin, Marian ^b   Pierga, Jean Yves ^a   Bonneterre, Marie Edith ^b   Marreaud, Sandrine ^d   Lacombe, Denis ^d   Fumoleau, Pierre ^c,d  

^a INSTITUT CURIE   (France)

^b CENTRE OSCAR LAMBRET   (France)

^c CENTRE GEORGES FRANÇOIS LECLERC   (France)

^d EORTC DATA CENTER   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

5 [3 (4 DIPHENYLACETYL 1 PIPERAZINYL) 2 HYDROXYPROPOXY]QUINOLINE; DOCETAXEL; GLYCOPROTEIN P INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DEHYDRATION; DOSE CALCULATION; DOSE LIMITING TOXICITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INFUSION; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TOXICITY; DYSPHAGIA; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; INFECTION; LEUKOPENIA; MAXIMUM TOLERATED DOSE; MODEL; MODIFIED FIBONACCI MODEL; ODYNOPHAGIA; PAIN; PEAK SERUM CONCENTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; STOMATITIS; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; P-GLYCOPROTEIN; PROSPECTIVE STUDIES; QUINOLINES; TAXOIDS; TREATMENT OUTCOME;

EID: 24344474823     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2316     Document Type: Article

References (19)

1. Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 1997;40 Suppl:S3-8.
2. Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001;58:931-59.
3. Bosch I, Croop J. P-glycoprotein multidrug resistance and cancer. Biochim Biophys Acta 1996;1288: F37-54.
4. Ford JM, Yang JM, Hait WN. P-glycoprotein-mediated multidrug resistance: experimental and clinical strategies for its reversal. Cancer Treat Res 1996;87:3-38.
5. Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 1997;40 Suppl: S13-9.
6. Sato W, Fukazawa N, Nakanishi O, et al. Reversal of multidrug resistance by a novel quinoline derivative, MS-209. Cancer Chemother Pharmacol 1995;35: 271-7.
7. Nakanishi O, Baba M, Saito A, et al. Potentiation of the antitumor activity by a novel quinoline compound, MS-209, in multidrug-resistant solid tumor cell lines. Oncol Res 1997;9:61-9.
8. Naito M, Tsuruo T. New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC 833. Cancer Chemother Pharmacol 1997;40 Suppl:S20-4.
9. Distefano M, Scambia G, Ferlini C, et al. Antitumor activity of paclitaxel (taxol) analogues on MDR-positive human cancer cells. Anticancer Drug Des 1998;13:489-99.
10. van Ark-Otte J, Samelis G, Rubio G, Lopez Saez JB, Pinedo HM, Giaccone G. Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes. Oncol Rep 1998;5:249-55.
11. Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 1991; 51:4226-33.
12. Boote DJ, Dennis IF, Twentyman PR, et al. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 1996;14:610-8.
13. Giaccone G, Linn SC, Welink J, et al. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin Cancer Res 1997;3:2005-15.
14. Greenberg PL, Lee SJ, Advani R, et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol 2004;22:1078-86.
15. Baer MR, George SL, Dodge RK, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002;100: 1224-32.
16. Sanson M, Napolitano M, Yaya R, et al. Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study. J Neurooncol 2000;50:245-9.
17. Crivellari D, Pagani O, Veronesi A, et al. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol 2001;12:353-6.
18. Kemper EM, Verheij M, Boogerd W, Beijnen JH, van Tellingen O. Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein. Eur J Cancer 2004;40:1269-74.
19. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999; 17:1061-70.